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Purpose: To evaluate the outcomes of different intravitreal injections for the treatment of retinal vein
occlusion including central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO).
Methods: PubMed, Cochrane, the metaRegister of ControlledTrials, and ClinicalTrials were searched for
intravitreal anti-Vascular Endothelial Growth Factor (VEGF) and steroids with relevant keywords and date
limitation of 2009-2018. Meta-analysis was performed on studies that met the defined inclusion criteria.
Main outcomes were visual acuity (VA) and central macular thickness (CMT).
Results: Out of 681 studies, 36 articles (including 21 reporting CRVO and 15 dealing with BRVO)
were selected for systematic review. All five intravitreal drugs including triamcinolone, dexamethasone,
ranibizumab, bevacizumab, and aflibercept showed improvement of CMT and VA as compared to placebo
or laser treatment. Six randomized controlled trials were selected for meta-analysis in RVO patients. The
pooled mean difference of visual improvement between sham and ranibizumab was 12.7 Early Treatment
for Diabetic Retinopathy Study (ETDRS) letters (95%CI: 11.00 to 13.2), and the pooled mean difference in
CMT reduction was 221𝜇m (95%CI: 153 to 284); both changes were significantly in favor of ranibizumab. The
pooled mean difference of visual improvement between bevacizumab and triamcinolone was 5.3 ETDRS
letters in favor of bevacizumab (95%CI: 16 𝜇m to 17.5 𝜇m). Triamcinolone led to 68.1𝜇mgreater CMT reduction
than bevacizumab (95%CI: 58 𝜇m to 76 𝜇m). However, none of these differenceswere statistically significant.
Conclusion: Treatment with anti-VEGF agents in RVO is superior to observation. No significant difference
was seen between the eyes treated with bevacizumab or triamcinolone based on these results.
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INTRODUCTION
Retinal vein occlusion (RVO) is caused by thro-
mosis in central, hemi-central, or branch retinal
veins.[1] In central retinal vein occlusion (CRVO),
the obstruction usually occurs at the level of
the lamina cribrosa, while in branch retinal vein
occlusion (BRVO), it involves a branch of the
central retinal vein.[1–3] The clinical manifestations
of RVO is largely related to the secondary eleva-
tion of Vascular Endothelial Growth Factor (VEGF)
levels in the vitreous and retina due to retinal
ischemia.[1] The following conditions have been
variably reported as associations of RVOs: sys-
temic hypertension, diabetes mellitus, hyperlipi-
demia, hyper-homocysteinemia, blood coagulation
disorders, systemic inflammatory disorders, glau-
coma, short axial length, and high body mass
index.[2–6] Two major consequences of RVO which
lead to decreased visual acuity (VA) are macular
edema (ME) and retinal ischemia. In eyes with non-
ischemic CRVO, VA improves significantly follow-
ing resolution of ME.[4, 6, 7] However, in the eyes
with ischemic CRVO, no significant association has
been found between the presence or absence
of ME and improvement in VA due to permanent
damage to macular ganglion cells.[7] Other fac-
tors may also affect the natural history of CRVO.
Demographic factors such as age or male gender,
systemic factors including vascular risk factors or
high levels of blood hematocrit, and ocular factors
such as macular pigmentary change, epiretinal-
membrane formation following long-standing ME,
retinociliary collaterals, and glaucoma have been
reported to be associated with poor functional
outcomes.[8] The development of anterior segment
neovascularization also has a detrimental effect on
visual outcomes.[7, 8] Based on the Branch Retinal
Vein Occlusion Study (BVOS) study, the visual
prognosis in BRVO is better than CRVO.[9] There-
fore, it is not surprising to observe relatively good
outcomes in the control group of large randomized
controlled trials (RCTs) such as the Study on the
Efficacy and Safety of Ranibizumab Injection in
Patients With Macular Edema Secondary to BRVO
(BRAVO). Visual acuity improvement in eyes with
macular BRVO is usually more marked than eyes
withmajor BRVO.[10] Ischemic insult tomacular gan-
glion cells, pigmentary degeneration, and devel-
opment of epiretinal membrane may adversely
affect the visual outcome in BRVO.[11] Various treat-
ments have been proposed for the management
of RVO-related ME and many RCTs have been
designed to compare these therapies and their
long-term outcomes. The selection of the most
efficacious therapy providing the best outcome in
clinical practice necessitates ophthalmologists to
be updated on the results of recent trials and adopt
a comprehensive approach toward the patient. In
the current study, we aim to provide an update on
recent trials addressing the management of RVO-
related ME, compare the outcomes of these trials,
and perform a meta-analysis on studies with similar
arms according to the pre-defined inclusion and
exclusion criteria.
METHODS
This systematic review and meta-analysis complies
with the Preferred Reporting Items for Systematic
Reviews and Meta-analyses (PRISMA) - 2009 rules.
Search Methods for Identifying the Studies
Two investigators (HR and MM) participated in
the literature search via PubMed, Cochrane, the
metaRegister of ControlledTrials, and ClinicalTri-
als in English language with date limitation of
2009-2018. In the search strategy which was
last conducted on March 21, 2018, we used
the MeSH term “retinal vein occlusion” and the
words “*RVO”, “*vitreal”, “*VEGF*”, “bevacizumab”,
“Avastin”, “ranibizumab”, “Lucentis”, “aflibercept”,
“Eylea”, “triamcinolone”, “implant”, and “Ozurdex”.
It should be noted that we only searched for the
most popular agents in clinical practice and not the
miscellaneous drugs presented in the case reports
or case series.
Selection of Studies for Systematic Review
All titles and abstracts were independently
screened by two co-authors (HR and MM) and the
potential relevance was judged. Any disagreement
between the two authors was referred to the
corresponding author (AL) for final decision. The
final list of included studies was re-evaluated to
ensure proper study selection. Only papers with
full-texts or abstracts in English were selected.
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Data Collection
Data was collected separately by HR and MM from
all included studies:
• First and corresponding authors, journal,
year, main criteria for inclusion in the study,
any exclusion criteria, number of eyes, treat-
ment arms, and length of the study.
• Means and standard deviations of changes
in corrected VA and central macular thick-
ness (CMT) changes from baseline.
Each article was evaluated carefully and rated by
the panel (HR, MM, and MY) according to the level
of evidence provided by the study. The level of
evidence was assigned to each study according
to the latest guidelines of the British Centre for
Evidence-Based Medicine;[12]
• Level I: well-conducted and designed ran-
domized clinical trials
• Level II: lower-quality randomized, well-
designed case-control, and cohort studies
• Level III: lower-quality cohort and case-
control studies and case series
Outcome Measurement
The mean change of VA from baseline was the pri-
mary outcome measure. The secondary outcomes
included: (1) The proportion of patients gaining
15 Early Treatment for Diabetic Retinopathy Study
(ETDRS) letters or more compared to baseline at
different time points; (2) Mean change of CMT on
optical coherence tomography (OCT) frombaseline
as the anatomical outcome measure.
Meta-analysis: Inclusion and
Exclusion Criteria
Studies were included in the meta-analysis if they
met the following criteria: (1) randomized controlled
clinical trials with level I of evidence, (2) mean
follow-up of six months or more, (3) compar-
ing anti-VEGF or intravitreal corticosteroid with
placebo or laser treatment for ME due to CRVO
or BRVO, (4) providing the proportion that gained
15 ETDRS letters or more, (5) providing changes
of VA and CMT in the treatment and sham groups
for calculating mean difference (MD), odds ratio
(OR), and 95% confidence interval (95% CI). Meta-
analysis was performed on studies with level I evi-
dencewith comparable arms andmethods. Studies
were excluded from meta-analysis if they were
retrospective, non-controlled, non-randomized, or
were not in English. We chose six months as
the minimum time point for meta-analysis. The
mean change in VA and CMT was measured as a




The methodological efficiency of studies was eval-
uated for the quality based on the modified Jadad
scoring system.[13, 14] Through this assessment tool,
we evaluated three main study characteristics
including randomization, blinding, and participant
dropout. Studies with Jadad score of three points
or more were considered as high-quality studies.
Also, a risk of bias summary was provided by each
data collector separately including selection bias,
detection bias, and attrition bias in order to assess
various potential sources of systemic-bias.
Heterogeneity Assessment
Both clinical and methodological heterogeneities
were assessed for meta-analysis. We considered I2
values more than 60% to indicate substantial sta-
tistical heterogeneity. The Random-effects model
was used for meta-analysis.
Statistical Analysis
All analyses were performed using the Stata (Stat-
aCorp. 2013. Stata Statistical Software: Release
13. College Station,TX: StataCorp LP). The mean
post value of the studied outcomes was extracted
from each study. Using the forest plots, the 95%
confidence interval of the difference of treatments
in each study and the pooled effect of all studies
were demonstrated. Heterogeneity of studies was
evaluated using Cochran’s Q-test and I-square
index. An I-square more than 0.70 or a P-value
< 0.05 was considered as the indication of het-
erogeneity. To compensate for the heterogeneity
of the results of the studies, the Random-effects
model was applied. The funnel plot (qualitative
method) and Egger’s regression test (quantitative
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method) were used for the evaluation of possible
publication biases.Whenever the bias was present,
the pooled mean value was adjusted using the
trimming method.
RESULTS
The combined searches yielded 681 studies which
decreased to 410 articles after the duplicates were
removed. The panel reviewed 131 articles in full
text based on the inclusion criteria. Of these,
36 articles (CRVO: 21 and BRVO: 15), 27 level I-
or II-rated studies were selected for systematic
reviewbased on the compatibility with the inclusion
criteria [Tables 1 and 2].
Studies with level I evidence and comparable
arms and methods were chosen for meta-analysis.
Meta-analysis was done on studies that com-
pared the effectiveness of bevacizumab versus
triamcinolone acetonide and ranibizumab versus
sham. Due to the heterogeneity in the dosages of
intravitreal steroid and follow-up periods, we were
not able to perform a meta-analysis on all RCTs;
six RCTs were selected for meta-analysis based
on the inclusion and exclusion criteria [Figure
1].
Medical Management in CRVO
Description of the Condition in CRVO
Macular edema is one of the main causes of
reduced VA in CRVO. It is presumed to be
a result of the hypoxia-induced capillary per-
meability after vein occlusion and subsequent
hemorrhage.[15] The most popular treatment in
CRVO is the intravitreal injection of an anti-VEGF,
such as bevacizumab, ranibizumab, and afliber-
cept. However, intravitreal steroid injection may
also be considered especially in areas without
access to anti-VEGF agents. Intravitreal dexam-
ethasone implant is another therapeutic choice for
CRVO-induced ME (CRVO-ME),[16] while other treat-
ments such as fibrinolytic or anticoagulant agents,
angiostatic agents, acetazolamide and isovolemic
hemodilution, have not been approved.[17] Some
surgical options were also suggested including
induced chorioretinal anastomosis, injection of a
fibrinolytic agent by direct venous cannulation, and
radial optic neurotomy; however, none of them
has been proven effective in the treatment of
CRVO-ME.[17] The summary of the interventional
studies on the management of CRVO-ME with
level I or II of evidence are presented in Table
1.
Intravitreal Corticosteroids
Triamcinolone. Intravitreal injection of steroids is
effective in CRVO-ME by reducing the capillary
permeability and inhibition of the VEGF expression.
In contrast to anti-VEGF drugs with specific site of
action, steroids suppress the expression of many
cytokines. However, they may cause cataract and
steroid-induced glaucoma. It should be noted that
the effects of intravitreal triamcinolone may last
up to nine months, depending on the dosage
applied.[18–20]
Ip et al[18] reported the results of the Standard
Care versus Corticosteroid for Retinal Vein Occlu-
sion (SCORE) study that compared 1 mg and 4
mg doses of preservative free intravitreal triam-
cinolone acetonide (IVT) with the observation for
ME-associated VA loss in perfused CRVO. At four-
month follow-up, the median reduction in CMT was
more in the 4 mg IVT group (P < 0.001). However,
at 12-month follow-up, there was no difference
in terms of CMT reduction and VA improvement
between the two triamcinolone groups. IVT led
to a reduction in ME with a moderate correlation
with VA. They reported that there was a sig-
nificantly higher percentage of patients requiring
IOP-lowering medications and also higher rates
of cataract development in the steroid groups,
especially in the 4 mg IVT group. Considering
these efficacy and safety findings, 1 mg IVT was
recommended in the treatment of CRVO-ME. In this
study, the interval between the last triamcinolone
application and the end of the follow-up period
varied. Hence, some eyes in the study groups
might have been out of the effective phase of the
triamcinolone injection at the evaluation time.
Ramezani et al[21] evaluated the effects of multi-
ple intravitreal bevacizumab (IVB) injections versus
IVT in the treatment of 86 eyes with ME due
to acute CRVO. It was interesting that the differ-
ences were statistically significant in patients with
ischemic CRVO in favor of the IVB group. At all
visits, mean IOP rise was significantly higher in the
IVT group in comparison with the IVB group. As a
result, they recommended repeated IVB injections,
specifically in ischemic cases.
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(n =131) 
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with reasons 
(n =95) 
Studies included in 
qualitave synthesis 
(n =36) 




Figure 1. PRISMA flowchart.
Source: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and
meta-analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. For more information, visit www.prisma-statement.org.
Ding et al[22] compared the safety and efficacy
of IVB and IVT in patients with CRVO. No statis-
tically significant difference was found during the
nine-month follow-up between the two treatment
groups. Quicker visual recovery and improvement
of CMT was observed in patients who underwent
IVT injection compared with patients who received
IVB. In addition, fewer injections were needed in
the IVT group (1.31 ± 0.48) in comparison with the
IVB group (2.38 ± 1.04). In this study, retreatment
with IVB was performed three months after the first
injection if persistent ME was observed, instead
of three consecutive monthly injections in the first
three months. Therefore, the IVB group might have
been undertreated in this study.
Dexamethasone Intravitreal Implant (Ozurdex).
Intravitreal dexamethasone implant is a slow-
release steroid in a biodegradable polymer form
that lasts about three to four months.[23] The results
of the Global Evaluation of implantable Dexam-
ethasone in Retinal Vein Occlusion with Macular
Edema (GENEVA) trial were reported by Haller et
al.[23] They evaluated the efficacy and safety of
intravitreal dexamethasone implant in two dosages
compared with placebo injection in eyes with RVO-
ME (either BRVO or CRVO). A total of 1,267 patients
with VA between 20/50 and 20/200 were enrolled.
Patients with dexamethasone implant (either 0.35
mg or 0.70 mg) improved significantly faster com-
pared to the placebo regimen. From the first month
to the third month of treatment, more eyes in the
dexamethasone implant group achieved 15 ETDRS
letters compared to the placebo group (P < 0.001);
the maximum response was observed at month
3. However, the proportion of eyes achieving 15
ETDRS letter improvement after six months was
not different between the three groups. The mean
VA improvement was more pronounced in the
dexamethasone groups compared to the placebo
group from month 1 to month 6 (P = 0.006); the
greatest difference was observed at the end of
the second month which was about seven ETDRS
letters. The mean decrease in CMT was also
marked significantly more in eyes receiving each
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dose of dexamethasone implant compared with
placebo at month 3; however, the difference was
not sustained up to month 6. It seemed that these
changes in CMT were parallel to changes in BCVA.
The observed clinical efficacy of dexamethasone
implant had a limited duration, lasting between 90
to 120 days with a gradual decline thereafter. How-
ever, the peak response was observed after three
months and was accompanied with the highest
incidence of IOP rise between days 60 to 90. This
study embraced a large proportion of non-ischemic
CRVO patients that led to encouraging outcomes,
but the use of dexamethasone in ischemic CRVO
remained questionable. Visual acuity improvement
was sustained after the extension of the GENEVA
study to 12 months by repeated injections of dex-
amethasone implant. On the other hand, complica-
tions were observedmore frequently with repeated
doses of dexamethasone implant, but these side
effects could be satisfactorily managed by either
surgery or medications. After the second dexam-
ethasone implant, a large number of patients were
able to maintain the visual gain of more than 15
ETDRS letters beyond six months although more
steroid-related complications might occur.[24]
In SOLO study (Functional and Anatomical
Results after a Single Intravitreal Ozurdex Injection
in Retinal Vein Occlusion), Bezatis et al evaluated
the efficacy period of Ozurdex (dexamethasone
implant) in both CRVO- and BRVO-related ME. Like
Geneva study, this study showed that early rein-
jection of dexamethasone implant after 16 weeks
instead of 24 weeks was required in most cases;
40.7% of the BRVO group and 15% of the CRVO
group required reinjection after 17.5 and 17.6weeks,
respectively.[25]
Hoerauf et al in COMRADE C study (Clinical
Efficacy and Safety of Ranibizumab Versus Dexam-
ethasone for CRVO) evaluated the efficacy of dex-
amethasone implant versus ranibizumab in eyes
with CRVO-ME.[26] They showed that although both
treatment groups had a similar outcome in the first
two months, the efficacy of ranibizumab sustained
throughout the study, while dexamethasone thera-
peutic effect decreased from month 3 onward. The
limitation was that all eyes in the dexamethasone
group were treated with only a single dosage
during the six-month period of the study. Based
on the GENEVA and SOLO studies, the effect of
treatment gradually decreases after three months
and re-injection is needed. In other words, in
clinical practice, dexamethasone re-implantation
might be required earlier than six months.
In a randomized clinical trial by Gado et al,
the efficacy of intravitreal dexamethasone implant
versus repeated bevacizumab injectionswere eval-
uated in six months. They showed that both drugs
provided the same effect on VA gain and CMT
reduction after the first six months of treatment
although there was a significantly higher rate of
IOP rise in the dexamethasone implant group com-
pared with the IVB group at three-six months.[27]
Anti-VEGF Agents
Ranibizumab. ROCC study (a Randomized Study
Comparing Ranibizumab to Sham in Patients with
ME Secondary to CRVO) was performed to com-
pare ranibizumab with placebo regimen in patients
with CRVO-ME. At each time point, BCVA was
improved in the ranibizumab group compared with
the visual loss in the sham group (P = 0.001).
Eighty percent of cases (n = 12) in the ranibizumab
group required more than three initial injections
(4.3 ± 0.9) during the study. They concluded
that monthly ranibizumab injection significantly
improved ME and BCVA; maintaining the initial
improvement would be possible with consecutive
repeated injections.[28]
Ranibizumab for the Treatment of Macular
Edema after Central Retinal Vein Occlusion CRVO
(CRUISE) trial compared the efficacy of ranibizumab
0.3 mg or 0.5 mg with placebo in CRVO-ME.[29]
After six months, the VA of patients treated with
either 0.3 mg or 0.5 mg ranibizumab improved
significantly more than the placebo group. Addi-
tionally, anatomical changes correlated well with
the visual improvements. Later, Campochiaro et
al[30] published the 12-month results of the CRUISE
trial. In this extension of the study, patients were
eligible to be treated with 0.5 mg ranibizumab on a
pro re nata (PRN) basis if BCVA was less than 20/40
or CMT was more than 250 𝜇m. The superiority
regarding the mean ETDRS letter gain after one
year was maintained in the ranibizumab treatment
groups compared with the placebo group. After 12
months, the mean reduction of CMT was similar
between the study groups. The number of needed
injections was of interest as it determined the
financial burden. The mean number of injections
among all randomized patients was 3.3 to 3.8 at
months 6 to 12 based on the PRN approach. As a
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result, ranibizumab was superior to sham based on
the visual improvement at months 6 and 12, and the
0.5 mg ranibizumab was a more effective regimen
in the treatment of CRVO-ME, based on this study.
HORIZON trial (Ranibizumab for Macular Edema
due to Retinal Vein Occlusions: Long-term Follow-
up) provided data regarding ranibizumab use in
24 months and analyzed the long-term safety and
efficacy of ranibizumab in RVO-related ME (either
BRVO or CRVO).[31] It was a multicenter single-
armed study with 304 patients from the BRAVO
and 304 patients from the CRUISE studies being
recruited. They were evaluated at three-month
intervals and were candidates for 0.5 mg intravit-
real ranibizumab if the recurrence of ME or a drop
in VA was identified. Indeed, HORIZON was an
extension study of the BRAVO and CRUISE studies.
In the second year, fewer ranibizumab injections
in patients with CRVO was associated with a more
prominent worsening of visual outcomes compared
to the BRVO patients. A reasonable explanation is
that retinal ischemia is more extensive in CRVO,
leading to a larger VEGF drive that requires more
frequent doses of ranibizumab injections. Hence,
fewer ranibizumab injections and reduced follow-
up in the second year of treatment resulted in a
decline in VA of CRVO patients.
A post-hoc analysis study based on the data
obtained by BRAVO and CRUISE trials evaluated
the effects of ranibizumab on RVO-related ME
(789 patients: BRAVO, n = 397; CRUISE, n = 392).
VA improvement was observed just after seven
days post-injection and was persistent up to 12
months by the PRN regimen. The time to first
gain of 15 ETDRS letters of VA in the CRVO
group was 4 months and in the BRVO group
was 5.2 months after repeated 0.5 mg monthly
ranibizumab injections. Overall, more than half
of the patients who received monthly regimen
achieved significant functional improvement after
the first six months of the treatment.[32]
Bevacizumab. Several retrospective and
prospective studies reported the efficacy of
intravitreal injection of bevacizumab in the
improvement of VA and reduction of CMT.[22, 33–35]
In a prospective controlled clinical trial by Epstein
et al,[36] after six months, three times more
patients in the study group had gained at least
15 letters than the sham group. The mean CMT
reduction was significantly more pronounced
in the bevacizumab group compared to the
control group. The authors continued the study
with a six-month extension period.[37] From 6
months to 12 months, all patients from both
groups were candidates to be treated with PRN
bevacizumab every six weeks. CMT reduction
was prominent in both sham/bevacizumab and
bevacizumab/bevacizumab groups. However,
vision improvement was more prominent in the
bevacizumab/bevacizumab group versus the
sham/bevacizumab group. Although anatomic
improvement occurred after crossing over of sham
patients to bevacizumab, functional improvement
was limited. Therefore, earlier treatment might lead
to better outcomes.
Rajacopare et al in CRAVE study (Bevacizumab
Versus Ranibizumab in the Treatment of Macular
Edema Due to Retinal Vein Occlusion)[38] com-
pared the efficacy of monthly ranibizumab or beva-
cizumab for RVO-ME in a randomized clinical trial.
After six months, changes in CMT and VA were not
different between the treatment groups. Although
the efficacy of bevacizumab and ranibizumab are
reported to be quite similar in the treatment of
CRVO-ME in many studies,[39–41] the use of beva-
cizumab in the management of RVO-ME remains
off-label.
Ding et al[22] evaluated the safety and efficacy of
IVT versus IVB for CRVO-ME. After nine months, 5
of the 16 IVT eyes and 12 of the 16 IVB eyes needed
re-treatment. The mean number of injections in
the triamcinolone group (1.3) was less than in
the bevacizumab group (2.4). BCVA improvement
occurred at all time points after the injections in
both study groups, and no significant difference
was observed between the two groups.
Some non-randomized studies reported more
chance for vision gain in eyes treated with a com-
bination of dexamethasone and IVB than eyes that
received dexamethasone implant monotherapy[42].
Aflibercept. The protein VEGF Trap-Eye (afliber-
cept) comprises key domains of human VEGF
receptors 1 and 2, fused with human IgG FC
fragment. Indeed, all isoforms of VEGF-A and
placental growth factor would be blocked by this
protein. The main advantage of aflibercept is its
longer duration of activity.[43] Hence, it may reduce
the dosing intervals of intravitreal injections in
comparison with ranibizumab and bevacizumab.
GALILEO (General Assessment Limiting Infiltration
of Exudates in Central Retinal Vein Occlusion
with VEGF Trap-Eye) and COPERNICUS (Vascular
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Endothelial Growth Factor [VEGF] Trap-Eye: Inves-
tigation of Efficacy and Safety in Central Retinal
Vein Occlusion) are multicenter randomized clinical
studies that evaluated the intravitreal aflibercept
effects in patients with CRVO-ME.[43–48]
In COPERNICUS study,[43] VA improvement and
macular thickness reduction after six months were
significantly more in the aflibercept treated eyes
than the control group. They also reported that
reduced ocular neovascularization was noted in
the aflibercept group. Later, Brown et al[44] reported
the 12-month results of COPERNICUS study in
which the previously established arms for the RCT
were eligible to be treated with PRN doses of
aflibercept 2 mg every four weeks from month
7 to month 12. After 12 months, the mean VA
improvement was 16.2 and 3.8 letters in the
aflibercept + PRN group and the sham + PRN
group, respectively. They concluded that fewer
injections of aflibercept after the loading period
could maintain the VA gain; however, a delay
in the treatment of ME could lead to irreversible
damage due to chronic edema and disintegrated
retinal layers. Heier et al[45] reported the 24-month
results of the study. After the first year, based on
the study protocol, patients were evaluated every
three months and were treated with aflibercept
if needed. The visual gain was significantly more
in the aflibercept/PRN group than the sham/PRN
group after two years (13 versus 1.5 letters in each
group, respectively). The mean number of PRN
injections was less in the aflibercept + PRN (2.7
± 1.7) compared with the sham + PRN (3.9 ± 2.0)
during months 7 to 12, while during months 13
to 24 the number of PRN injections were 3.3 ±
2.1 versus 2.9 ± 2.0 in the two groups, respec-
tively. They also showed that the functional and
anatomic improvements, after fixed dosing through
six months, followed by PRN regimen and monthly
monitoring frommonths 7 to 12, were reduced after
continued PRN regimen and a reduced monitoring
frequency frommonths 12 to 24 [Table 1]. They sug-
gested a beneficial effect of anti-VEGF treatment
in either group of patients with ischemic or non-
ischemic CRVO; this effect was significantly lower
if treatment was started with a delay in both sub-
groups. Considering the time between diagnosis
and treatment, they reported that the proportion of
patients with 15 letter gain or more after six months
was significantly more in patients who received the
first intravitreal aflibercept injection during the first
two months of diagnosis. They also showed that
aflibercept is beneficial even in patients with poor-
presenting VA of less than 20/200.
In a similar double masked RCT named
GALILEO, patients with CRVO were randomized to
intravitreal aflibercept 2 mg or placebo monthly for
six months. Based on GALILEO reports, the mean
change in BCVA and CMT were more marked in
patients receiving aflibercept than the sham group
at week 24 (P = 0.0001).[46] From months 7 to 12,
patients were monitored monthly; the aflibercept
group was treated with the intravitreal drug on
a PRN basis, and the placebo group continued
to receive sham. From months 13 to 18, patients
were monitored bimonthly, and both groups were
treated with intravitreal aflibercept PRN. This
study showed that the functional and anatomic
improvements after fixedmonthly dosing in the first
six months were largely sustained even with the
extension of the treatment intervals. Patients with
a baseline BCVA of 20/200 or worse had a greater
visual improvement after 12 months compared
to patients with a baseline BCVA of better than
20/200. Similar to COPERNICUS study, this study
revealed that, although delayed treatment with
aflibercept led to anatomic improvement, the
functional improvement was limited, and the effect
could persist for two years. It showed that more
improvement of vision might occur if treatment was
started earlier.[47, 48]
Based on these studies, significant visual and
anatomic improvements occurred in the first six
months with fixed monthly aflibercept injections.
These improvements were largely maintained by
PRN aflibercept injection with a mean of 2.5 to
2.7 injections in the next six months. Therefore,
a monthly loading dose for up to three months
followed by bimonthly aflibercept may have similar
efficacy to that of monthly ranibizumab.[47, 48]
The efficacy of bimonthly intravitreal aflibercept
and ranibizumab in CRVO-ME was evaluated by
Saishin et al. They concluded that although no sig-
nificant difference was observed in visual improve-
ment between the two groups, VEGF may not be
completely neutralized by bimonthly injections of
ranibizumab in all patients with CRVO, which may
lead to the recurrence of ME.[49]
Recently, in SCORE II study, the efficacy of
monthly bevacizumab was compared with monthly
aflibercept in patients with CRVO-ME. Based on
this study, monthly bevacizumab was not inferior to
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aflibercept regarding visual improvement after six
months. SCORE II extension studies probably will
compare outcomes of these anti-VEGF agents after
six months, using regimens other than monthly
dosing.[50]
In a recent report of a randomized clinical
trial, the injection frequency of aflibercept and
ranibizumab in the treatment of CRVO-ME was
investigated. Patients were allocated to receive
either intravitreal aflibercept (2mg) or ranibizumab
(0.5mg) in a treat and extent regimen. After 18
months, the number of injections was significantly
lower in the aflibercept group (10.9) compared to
the ranibizumab group (14.4) (p = 0.001). The mean
treatment interval was significantly longer in the
aflibercept group compared with the ranibizumab
group (10.0 versus 6.6 weeks) (p = 0.001). The
mean changes in BCVA and CMT were similar
between the groups. The authors concluded that
the application of treat and extent regimen with
aflibercept in eyes with CRVO might reduce the
treatment burden and, to some extent, the need for
close monitoring of patients.[51]
Medical Management of BRVO
Similar to CRVO, ME is the main reason for visual
loss in BRVO. Based on the Branch Vein Occlusion
Study (BVOS), macular grid laser photocoagulation
was an effective treatment in branch retinal vein
occlusion-related macular edema (BRVO-ME).[9]
Pharmacologic intervention started with the use
of corticosteroids: triamcinolone and dexametha-
sone. Multiple formulations of IVT were used as
an off-label drug in the treatment of BRVO-ME.
The intravitreal dexamethasone sustained-release
implant was approved in 2009 for the treatment of
BRVO-ME by the U.S. Food and Drug Administra-
tion (FDA).[23, 24]
In recent years, anti-VEGF agents (ranibizumab,
aflibercept, and bevacizumab) have become the
most popular therapeutics for BRVO-ME. In addi-
tion, other modalities have been evaluated in the
treatment of BRVO including chorioretinal anas-
tomosis with laser, separation of the common
adventitia of the crossing artery and vein with
removing the cortical vitreous following pars plana
vitrectomy, and intra-vascular injection of t-PA
through cannulation of the veins.[52, 53] Interven-
tional studies on the management of BRVO-ME
with levels I or II of evidence are summarized in
Table 2.
Intravitreal Corticosteroids
Triamcinolone. In a study designed for the treat-
ment of BRVO-ME, Scott et al compared the effec-
tiveness of standard care (grid laser photocoagu-
lation) versus corticosteroid for retinal vein occlu-
sion (SCORE) study report 6.[54] This study was
conducted to evaluate the efficacy of two doses
of preservative-free intravitreal triamcinolone with
grid photocoagulation in BRVO-ME patients with
BCVA between 20/40 and 20/400 and CMT of
more than 250 𝜇m. At month 12, the VA improve-
ment was similar between the groups; however,
more complications were observed with 4 mg
triamcinolone (35% with cataract progression and
41% with the need for IOP-lowering medications).
During the first year, none of the treated eyes
required glaucoma surgery. However, after 24
months, two eyes in the 4 mg IVT group required
surgical interventions. SCORE concluded that the
therapeutic efficacy was quite similar in two groups
although the 4 mg triamcinolone might lead to
more adverse effects.
Dexamethasone Intravitreal Implant (Ozurdex)
In the GENEVA study, 830 patients from a total of
1,267 patients (66%) with RVO, who had a BRVO for
at least six weeks, were randomized to receive dex-
amethasone implant 0.7 mg, 0.35 mg, or placebo.
Eyes with a history of laser photocoagulation were
not excluded in this study. Visual improvement of
15 letters or more was achieved faster in both
dexamethasone implant groups than the placebo
group (P < 0.001). In addition, the percentage of
eyes with sustained VA improvement was higher
in the dexamethasone implant groups compared to
the sham group after the third month (P < 0.001).
The therapeutic effect of these implants was not
sustained after six months. However, frommonths 1
to 6, the overall mean increase in VA from baseline
was significantly higher in the dexamethasone
implant groups compared with the placebo group.
In eyes with BRVO-ME with a duration less than
90 days, even greater functional improvement
might be achieved with dexamethasone implants
comparing to eyes with ME lasting more than
three months based on the subgroup post-hoc
analysis. The study did not mention CMT in each
BRVO subgroups, but overall (i.e., combined CRVO
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and BRVO) a significant reduction in CMT was
seen in both implant groups compared with the
sham group in the first three months. However,
after six months, anatomical changes did not differ
significantly between the groups.[24]
Two years later, Guignier et al compared the
dexamethasone implant with three monthly IVB
injections in the treatment of BRVO-ME. The mean
visual gain and CMT reduction was significantly
more pronounced at the one-month visit in the
intravitreal dexamethasone implant group which
was compatible with a faster visual improvement.
However, no difference was observed between
the two groups at months 3,4, and 6. Despite no
difference in mean VA between the study groups
at month 6, a significantly higher proportion of
eyes treated with bevacizumab gained 15 letters
or more compared with the dexamethasone group.
More reinjections at month 4 were needed with
the dexamethasone implant comparedwith the IVB
treatment.[55]
Anti-VEGF Agents
Ranibizumab. Campochiaro et al[56] published the
results of phase III of BRAVO study that compared
two ranibizumab doses of 0.3 mg and 0.5 mg
with placebo in BRVO-ME. In cases of progressive
refractory edema at month 3, rescue grid laser was
done. After six months, the BCVA improvement and
CMT reduction were higher in both ranibizumab
groups compared with the placebo (P < 0.0001).[57]
After six months of initial monthly dosing, patients
were switched to a PRN injections; 0.5 mg of
ranibizumab was injected in the placebo group,
while the 0.3 mg and 0.5 mg groups were treated
with their original doses. BCVA improvement at
six months was maintained in the ranibizumab
groups after one year. After starting ranibizumab
in the sham group, vision improved; however, this
improvement was less than the visual gain in the
ranibizumab groups (P < 0.01). The mean CMT
change was higher in the 0.3 mg and 0.5 mg
groups compared to the sham group (P < 0.05) at
six months.
HORIZON study[31] was a two-year extension trial
of the BRAVO and CRUISE studies. In the BRVO
arm of the study, 304 patients were given evalu-
ation at three-month intervals and were candidates
for 0.5 mg ranibizumab if recurrence of ME or a
drop in VA was identified. HORIZON study was
not completed and led to the variable follow-up
periods among the study patients; about 63% of
patients (n = 205) from BRAVO trial completed
the period of 12 months in the HORIZON study.
The mean number of injections in each of the
previous BRAVO groups ranged from 2.0 to 2.4
during 12 months of the trial. Visual acuities were
significantly increased compared with the BRAVO
baseline BCVA in each treatment group. However,
considering the baseline values of the HORIZON
study, no change or even slight decline in VA was
observed in the second year. The study suggested
that maximal VA improvement that can be achieved
by monthly injections may decline slowly with
decreased follow-up visits.
Comparison of 0.5 mg ranibizumab with or
without adjunctive macular laser therapy, and laser
therapy alone was done by Tadayoni et al.[58] Three
monthly intravitreal ranibizumab injections were
performed in the ranibizumab groups and subjects
were subsequently re-treated PRN according to the
designed protocol. At sixmonths, both ranibizumab
groups showed significant visual improvement
compared to the laser only group (P < 0.0001).
There was no difference in the number of injections
between the two ranibizumab groups. Anatomi-
cally, the mean CMT reduction at six months was
significantly more in the ranibizumab groups than
the laser group (P < 0.0001).
ITan et al[59] compared intravitreal 0.5 mg
ranibizumab with grid laser in BRVO-ME over
one year. At the fourth and sixth months, more
patients in the grid laser group (68.4% and 50.0%)
received additional grid laser compared with the
ranibizumab group (6.7% and 8.3%). They con-
cluded that significant and sustained functional
and anatomic improvements were provided by the
intravitreal ranibizumab in eyes with BRVO-ME.
In the Ranibizumab for Branch Retinal Vein
Occlusion Associated Macular Edema Study
(RABAMES), patients with BRVO-ME were
randomized to treatment with three monthly
intravitreal 0.5 mg ranibizumab injections or grid
laser or both 60. The mean BCVA improvement
after six months was significantly higher in
the ranibizumab group compared to the other
groups. The combination group required fewer
laser retreatments at month 2 compared with
the grid laser group (20% versus 70%). They
concluded that ranibizumab might be more
efficient in visual improvement compared to grid
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laser photocoagulation. Laser combined with
ranibizumab neither augmented VA gain and
macular thickness reduction nor did it prevent
recurrence of ME. CMT increased gradually after
stopping the injections in ranibizumab groups,
while visual improvement was sustained, indicating
that functional deterioration may occur after the
structural disintegrities. Reinjection of ranibizumab
after the initial loading dosage, even with a proper
response to treatment, may be necessary based
on the visual and anatomical changes.
Bevacizumab. Multiple studies[61–63] evaluated
the efficacy of bevacizumab in BRVO-ME although
most of them are retrospective or with small sample
size. Based on a prospective study by Russo et
al,[63] 30 eyes with BRVO were randomized to
treatment with monthly IVB or macular grid laser
over 12months. At all time-points of the study, more
improvement in BCVA and CMT was observed in
the bevacizumab group than the laser group (P <
0.005).
In a prospective randomized interventional
study,[64] PRN IVB and subthreshold grid laser
were compared as second line therapy for ME
in BRVO. This study showed better anatomic and
functional results in the IVB group compared to the
subthreshold grid laser group.
In a prospective randomized clinical trial byMAR-
VEL group, the efficacy of IVB and ranibizumab
(IVR) in BRVO-ME was compared. The number of
injections was not significantly different between
the treatment groups (3.2 ± 1.5 versus 3.0 ± 1.4,
respectively; P = 0.55). There was a significant
improvement in VA and CMT in eyes that under-
went either bevacizumab or ranibizumab injection
without any significant difference between the two
drugs.[65]
In one study, patients with BRVO-ME were ran-
domly assigned to receive 4 mg IVT monotherapy
(n = 17), 1.25 mg IVB monotherapy (n = 14), or
a combination of 2 mg IVT and 1.25 mg IVB
(n = 21). After one month, all groups showed
significant improvement in VA and CMT. At six
months, the significant reduction in the CMT was
sustained while only the bevacizumab monother-
apy group demonstrated significant improvement
in the BCVA. Based on these results, at six months,
IVB might lead to better functional outcomes com-
pared to the other regimens in this study. Ocular
side effects occurred more frequently in the 4
mg triamcinolone group compared to the other
groups. A mean IOP increase of 1.4, -0.1, and 0.5
mmHg occurred in three groups, respectively. Also,
cataract progression occurred 36%, 8%, and 10% in
the three study arms, respectively.[66]
In a study by Higashyama,[67] eyes with BRVO-
ME were randomly allocated to receive 4 mg IVT
or 1.25 mg IVB with 12-month follow-up; additional
injections were administered between 3 and 12
months if it was indicated based on the study cri-
teria. After 12 months, the functional improvement
from baseline was significantly higher in the IVB
group, although no significant difference was seen
in CMT reduction between the groups. Therefore,
Intravitreal injection of bevacizumab may be a
better treatment than that of triamcinolone ace-
tonide for BRVO-ME. Given the three-month delay
in resuming the treatment after the initial injection,
under-treatment of patients should be considered
in the appraisal of the results of this study.
Aflibercept. VIBRANT Study[68] (study to Assess
the Clinical Efficacy and Safety of VEGF Trap-
Eye in Patients with BRVO) was a double-masked
randomized trial that evaluated the six-month out-
comes of intravitreal aflibercept versus macular
laser in BRVO-ME. After six months, monthly
aflibercept injection was associated with more
functional and structural improvements than mac-
ular grid laser in eyes with BRVO-ME.
In the second phase of this study, after the first
six months, aflibercept injection was allowed for
patients primarily randomized to laser.[69] Afliber-
cept was injected every eight weeks instead
of every four weeks in the primary aflibercept
group. It was interesting that even with the eight-
week interval regimen, the functional and anatom-
ical improvements gained with monthly injections
during the initial six months of the study were
maintained. In addition, the laser/aflibercept group
had significant VA improvement after initiating
aflibercept; however, the improvement was still
significantly less than in the eyes that received
aflibercept from the beginning of the study (P =
0.02), indicating the importance of earlier initiation
of treatment. At week 52, the mean CMT reduction
from baseline was -283 and -249 𝜇m in the afliber-
cept and laser/aflibercept groups, respectively. In
conclusion, anatomical outcome was not signifi-
cantly changed even with deferral of the treatment,
but maximum visual improvement which could be
achieved with early aflibercept injection might not
be attained in the deferral group.
J  O  V R Volume 14, Issue 3, July–September 2019 357
Intravitreal Medications for RVO; Lashay et al
Meta-analysis
Ranibizumab versus Sham Injections
Participants. A total of 555 patients with RVO-ME
were enrolled in three studies including ROCC,[28]
BRAVO,[56, 57] and CRUISE.[29, 30] The baseline
characteristics of participants in these trials were
not significantly different concerning age, gender,
and systemic factors (e.g., Ischemic heart disease,
hypertension, and diabetes mellitus).
Mean Change in BCVA and CMT at Six Months.
All three studies reported changes in BCVA and
CMT and reported measures of dispersion (SD or
95% CI). At month 6, the pooled mean change
in BCVA ranged from -2 to +7.3 letters and +11 to
+18.3 letters in the sham and treatment groups,
respectively. The highest gain in VA was observed
within two months of treatment with anti-VEGFs,
with no deterioration thereafter to six months in all
studies. After six months, the pooled MD between
anti-VEGF and sham was 12.7 letters (95% CI: 11.00
to 13.2). As the statistical heterogeneity was not
considerable (I2 = 0%, P = 0.84), data was combined
in the meta-analysis because the direction of effect
was similar for all trials [Figure 2a]. Results showed
superiority of ranibizumab compared to the sham.
The pooled mean CMT improvement at six
months ranged from -117 to -167 𝜇m and -304
to -452 𝜇m in the sham and treatment groups,
respectively. Meta-analysis of the data showed that
patients who underwent ranibizumab injection had
more reduction of pooled mean CMT compared
with the sham group, (95% CI: -153 to -284 𝜇m).
There was significant statistical heterogeneity (I2
= 80%, p < 0.01) [Figure 2b]. Hence, we used the
Random-effect model. This represents that, based
on anatomical changes, anti-VEGF treatment is
associated with clinically significant benefits com-
pared with sham at six months.
Bevacizumab versus Intravitreal
Triamcinolone
Participants. A total of 149 patients, with ME sec-
ondary to RVO, were enrolled in three studies
(Ramezani et al,[21] Ding et al,[22] and Cekic[66] et al).
The baseline characteristics of participants in these
trials were also similar.
Mean Change in BCVA and CMT at Six Months.
All three studies reported changes in BCVA,
CMT, and measures of dispersion (SD or 95% CI)
(Ramezani et al, Ding et al, and Cekic et al). The
pooled mean change in BCVA letter score at six
months ranged from +9 to +48 letters and +23.5 to
+32 letters in the triamcinolone and bevacizumab
groups, respectively. At six months, the pooled MD
between bevacizumab and triamcinolone was 5.3
letters in favor of bevacizumab (95% CI: -16 to 17.5).
The statistical heterogeneity was not considerable
(I2 = 50.3%, p = 0.13). Since the direction of effect
was the same for all of the studies, we combined
data in the meta-analysis [Figure 3a]. There was
no significant difference in visual improvement
between the two therapies.
The pooledmean reduction in CMT at sixmonths
ranged from a -75 to -450 𝜇m and -132 to -
408 𝜇m in the triamcinolone and bevacizumab
groups, respectively. Meta-analysis of the data
suggests that the pooled mean CMT reduction
was significantly more in the triamcinolone groups
compared with the bevacizumab groups during the
first month, with no significant differences in mac-
ular thickness after six-months follow-up. Patients
treated with triamcinolone had a pooled mean
reduction in CMT of -68.1 𝜇m more than patients
treated with bevacizumab, (95% CI: -58 to -76 𝜇m).
There was a significant statistical heterogeneity (I2
= 72.1%, p = 0.02) [Figure 3b]. Therefore, Random-
effect model was used. Based on the anatomical
changes, no clinically significant superiority of IVB
over triamcinolone injections was observed at six
months.
DISCUSSION
Many pharmaceutical agents have been used for
the treatment of RVO-ME; however, three modali-
ties including intravitreal ranibizumab, aflibercept,
and dexamethasone implant are FDA approved.
The functional and anatomical results of random-
ized controlled trials of the five most common
pharmaceutical agents used in the treatment of
RVO-ME are summarized in Tables 1 and 2. Almost
all of them could improve the vision and reduce the
macular thickness comparedwith sham injection or
macular grid laser photocoagulation at months 6,
12, and 24. In addition, based on seven major RCTs
including BRAVO, CRUISE, HORIZON, Epstein et
al, COPERNICUS, GALILEO, and VIBRANT, ear-
lier treatment with these agents may lead to
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Figure 2. Forest plot displaying pooled summary estimates with ranibizumab treatment versus sham injection at 24 weeks. (a)
Regarding VA, there was no significant heterogeneity (I2 = 0%, p = 0.84). Due to small number of included studies, either fixed-
effect or random-effect analysis was applied or the overall 95%CI was meaningful (-0.35 to -0.01). (b) Regarding CMT, there was
significant heterogeneity (I2 = 80%, p < 0.01), hence, the random-effect model was used and the overall 95%CI was meaningful
(-1.37 to -0.46). CI, confidence interval; CMT, central macular thickness; VA, visual acuity
better outcomes.[29–31, 36, 37, 43–48, 56, 57, 68, 69] Signif-
icant ocular or systemic adverse effects of anti-
VEGF agents are rare. Intraocular pressure rise
and cataract progressionmostly occurred following
intravitreal corticosteroid injections.
Based on the SCORE study,[18] the proportion of
patients with CRVO gaining 15 letters of ETDRS
after 12 months was 6.8%, 26.5%, and 25.6% in
the observation, 1 mg IVT, and 4 mg IVT groups,
respectively. At four months, the mean reduction
in CMT was greater in the 4 mg IVT group.
However, no difference was seen regarding CMT
improvement among the treatment groups after
12 months. In the triamcinolone-treated patients,
authors reported a reduction inMEwith amoderate
correlation with VA; however, there was a sig-
nificantly higher percentage of patients requiring
IOP-lowering medications and a higher rate of
cataract development in the 4 mg IVT group.
Hence, the authors suggested 1 mg IVT injection
for ME secondary to CRVO. In eyes with BRVO,
the comparison was made between intravitreal
triamcinolone and laser treatment. No significant
difference was found although the 4 mg IVT group
again was associated with the highest rate of
adverse events.[18, 54] Comparing intravitreal triam-
cinolone and anti-VEGF agents, more functional
improvement may occur with anti-VEGF injection
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Figure 3. Forest plot displaying pooled summary estimates with bevacizumab treatment versus triamcinolone injection at 24
weeks. (a) Regarding VA, since there was no significant heterogeneity (I2 = 50%, p = 0.13), either fixed-effect or random-
effect analysis was applied or the overall 95%CI was not meaningful (-0.08 to 0.87). (b) Regarding CMT, there was significant
heterogeneity between included studies (I2 = 72%, p = 0.02) and thus, the random-effect model was used and the overall 95%CI
was not meaningful (-0.80 to 0.48). CI, confidence interval; CMT, central macular thickness; VA, visual acuity
although triamcinolone may be accompanied with
faster structural improvement.[21, 22, 66]
Dexamethasone implant was compared with
the sham treatment in RVO eyes in the GENEVA
study.[23, 24, 55] After three months, both structural
and functional improvements were significantly
higher in eyes treatedwith dexamethasone implant
compared to sham injection, but this effect was
not maintained after six months. The maximum
therapeutic effect of intravitreal dexamethasone
implant is about 12 weeks after injection. Therefore,
treatment repetition is necessary even with dexam-
ethasone implantable agents. The peak response
observed at three months is accompanied by
the highest incidence of IOP rise and cataract
formation. The therapeutic effect (both structural
and functional) was greater in eyeswith CRVOeyes
than in eyes with BRVO.
Patient selection in the GENEVA study was not
randomized for retinal ischemia; a large propor-
tion of non-ischemic RVO patients were enrolled.
Hence, the study didn’t address the use of Ozurdex
in ischemic CRVO patients. A post-hoc analysis
showed that dexamethasone implantation earlier
than three months after the BRVO occurrence
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was associated with greater VA improvement com-
pared with the eyes with longer duration of ME.
According to the COMRADE study,[26] anti-VEGF
and dexamethasone implant treatment groups had
a similar outcome in the first two months, however,
dexamethasone’s efficacy decreased from month
3, while ranibizumab maintained its efficacy up
to month 6. It showed that dexamethasone re-
implantation might be required earlier than six
months. The SOLO study also reported early rein-
jection of dexamethasone implants in most of the
cases[25]. In the study by Guignier et al, a higher
percentage of eyes with BRVO achieved 15 letters
or more in the IVB group (30%) compared with
the dexamethasone group (11%) after 6 months.[55]
Although faster functional and anatomical recovery
during the first month was observed in eyes that
received dexamethasone implant compared to the
IVB-treated eyes, the reinjection rate at fourmonths
was also higher with dexamethasone.
In cases undergoing treatment with anti-
VEGF injection, various protocols have been
suggested. These protocols include loading doses
of three to six monthly injections, followed by
re-injections on a PRN basis according to the
functional and structural changes. It seems that
aflibercept injection can be performed at longer
intervals without a significant reduction in its
efficacy. Although the “treat-and-extend” regimen
is frequently applied in anti-VEGF treatment in
age-related macular degeneration, this protocol
has also been recently used in ME due to RVOs
using aflibercept with good outomes.[51] All trials
showed that repeated anti-VEGF injection was
associated with significant improvement in the
functional outcomes at six months compared
to the placebo. The functional improvement
was also accompanied by favorable structural
outcomes.[18, 23, 24, 29, 30, 36, 37, 43–48, 50, 54, 56, 57, 68, 69]
The impact of treatment delay was evaluated
in some studies including VIBRANT,[68, 69]
COPERNICUS,[43–45] EPSTEIN,[36, 37] and
GALILEO.[47, 48, 64] These RCTs suggested that
a shorter interval between the diagnosis and the
treatment of RVO-ME was associated with the
greatest benefit of anti-VEGFs. The extension of
main studies on anti-VEGFs in which the control
group received sham injections for six months
and then were switched to PRN regimen between
months 7 and 12, further confirmed this evidence.
Postponing anti-VEGGF therapy for six months
could still have a good structural outcome with
no significant difference between the treatment
groups at month 12. In contrast, while functional
outcomes improved with switching to PRN anti-
VEGF injections after six months in the sham
group, these outcomes remained significantly
lower at one year compared with the groups
treated with anti-VEGF agents from the outset
(COPERNICUS,[43–45] CRUISE,[29, 30] and Epstein et
al[36, 37]).
In the HORIZON[31] study (the 24-month exten-
sion of CRUISE and BRAVO studies), visual out-
comes, but not macular thickness, worsened in the
second year of treatment especially in the CRVO
arm. This may be due to the reduced efficacy of
anti-VEGFs during the treatment course. The other
reason may be lower treatment frequency from
months 12 to 24, especially in patients with CRVO.
As we know, the non-perfusion area of retina is
usually larger in CRVO than in BRVO, and this
causes a higher concentration of VEGF.[7] There-
fore, more intravitreal injections may be needed in
the second year of treatment of eyes with CRVO-
ME than thosewith BRVO-ME. Regarding iris or reti-
nal neovascularisation or neovascular glaucoma,
anti-VEGF therapy led to a significant reduction
of neovascular complications compared to the
sham treatment at six months (COPERNICUS,[43–45]
CRUISE,[29, 30] Epstein et al,[36, 37] GALILEO,[46–48]
ROCC,[28] and VIBRANT[68, 69]). In eyes treated with
aflibercept, the visual and anatomical improve-
ments that occurred within the first 24 weeks of the
study with monthly 2 mg dosing were maintained
with bimonthly dosing.
Comparison of Studies with Different
Treatment Modalities
A direct comparison between CRUISE
(ranibizumab) and COPERNICUS/GALILEO
(aflibercept), GENEVA (dexamethasone), SCORE
(triamcinolone)[18, 24, 29, 44, 47] is not appropriate due
to several key differences in the study designs,
protocols, and population. For instance, eyes with
more severity of ischemia (e.g., the presence of an
RAPD) and more chronic disease were not enrolled
in the BRAVO study but were allowed in SCORE.
Hence, it is not surprising to see better results in
BRAVO study. Also, longer follow-up periods in
the SCORE might have led to under-treatment.
Likewise, in the GENEVA study, in the first six
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months of the study, only a single treatment with
dexamethasone implant was allowed, probably
resulting in the under-treatment as the implant’s
peak effect is at two to three months.
In the CRUISE[29, 30] trial, patients with sustained
ME of more than 12 months or an RAPD were
excluded, while prior treatment with anti-VEGF
therapy was not defined as an exclusion criteria.
In contrast, in COPERNICUS/GALILEO[43–48] trials,
patients were specifically excluded if they had
sustained ME of more than nine-months duration
or prior anti-VEGF treatment, and the presence
of an RAPD was not mentioned in the exclusion
criteria.[70, 71]
It is also not possible to compare the results
between CRUISE and SCORE as CRUISE study
might have included healthier eyes compared with
SCORE; in CRUISE trial (but not in SCORE), patients
were excluded if they had ME for more than 12
months or an RAPD (probably indicating extensive
capillary dropout and ischemia); follow-up and re-
treatment in CRUISE was monthly, but it was
implemented every four months in the SCORE.
Therefore, direct comparison of these studies may
lead to a misjudgment.[70]
Almost all trials reported that the greatest reduc-
tion in CMT occurred within a month of the first
injection. Also, the CMT improvement was sus-
tained during the treatment period. However, this
is in contrary to the observed course of CMT
changes in the control groups, who demonstrated
a smoother and linear reduction in CMT over the
time.
In this study, meta-analysis showed that treat-
ment with ranibizumab was associated with more
anatomical and functional improvement compared
to the sham after six months, while there was no
significant difference in anatomical and visual out-
comes between bevacizumab and triamcinolone
after six months. Although inclusion criteria for
meta-analysis was narrowed to permit including
comparable studies with similar arms, it should be
noted that some variables (i.e., the time needed
to wait before starting the treatment) were not
matched and could be a potential source of bias.
SUMMARY
This systematic review and the meta-analysis
demonstrates that treatment with anti-VEGFs pro-
vides significant structural and functional gains
compared to the observation in eyes with RVO.
There was no significant difference between eyes
treated with bevacizumab and intravitreal corticos-
teroid based on this meta-analysis. However, it
seems that repeated anti-VEGF injections, espe-
cially for ischemic cases, may be accompanied with
better visual outcomes and fewer side effects in the
long term.
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